+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005



Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005



Journal of Neuro-Oncology 101(1): 117-123



The purpose of this study was to describe the incidence and survival of primary Central Nervous System (CNS) malignancies using data from the population-based cancer registry for Girona province (north-east Spain).We included all cases of primary CNS malignancies registered between 1994 and 2005. Pathological diagnoses were reviewed and grouped according to the 2007 WHO Classification. Meningeal, soft tissue tumours, spinal cord tumours and primary CNS lymphoma were not included. Cases notified only by death certificate were excluded from the survival analysis. Kaplan and Meier survival curves were calculated from date of diagnosis to death or end of study (31 December 2005), as was relative survival. A total of 493 new CNS cancer patients were registered during the study period: 49.3% astrocytic, 3.4% oligodendroglial and oligoastrocytic tumours, 2.6% ependimal tumours, 3.7% embryonal tumours, 0.2% choroid plexus and 41% without histological confirmation. The mean age (in years) for embryonal tumours was 18.17 years, these being the younger patients in the sample, and 66.34 years for those without histological confirmation, the older patients. Overall, the age standardised incidence rate was 5.88 cases/100,000 people/year (men = 6.81; women = 4.99) with an increasing trend by age until the 70-74 age group. Five-year observed survival rates were: 14.6% for astrocytic tumours, 35.7% for oligodendroglial and oligoastrocytic tumours, 41.0% for ependymal tumours, 32.4% for embryonal tumours and 7.5% for those without histological confirmation (log rank test: P < 0.001). Five-year observed survival rates for astrocytic tumours were analyzed separately by tumour grading, with 37% for diffuse astrocytoma, 7.1% for anaplastic astrocytoma and 4.7% for glioblastoma (log rank test: P < 0.001).Our results show that astrocytic tumours are most frequently diagnosed and glioblastoma patients have the worst survival figures for the area covered by our population cancer registry.The high observed incidence of histologically unverified tumours is most probably due to easy access to state of the art CNS imaging in our area.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055055219

Download citation: RISBibTeXText

PMID: 20544374

DOI: 10.1007/s11060-010-0240-7


Related references

Patterns of increased incidence and survival of cutaneous melanoma in Girona (Spain) 1994-2013: a population-based study. Clinical and Translational Oncology 2018, 2018

Trends in incidence and survival analysis in non-melanoma skin cancer from 1994 to 2012 in Girona, Spain: A population-based study. Cancer Epidemiology 45: 6-10, 2016

Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013). Clinical and Translational Oncology 20(12): 1628-1630, 2018

Incidence and survival of central nervous system tumors in childhood and adolescence in Girona (Spain) 1990-2013: national and international comparisons. Clinical and Translational Oncology 2019, 2019

Social inequality and incidence of and survival from tumours of the central nervous system in a population-based study in Denmark, 1994-2003. European Journal of Cancer 44(14): 2050-2057, 2008

Population-based incidence of lymphoid neoplasms by histological subtypes in Girona (Spain), 1994-2001. Medicina Clinica 126(1): 5-12, 2006

Nationwide Population-Based Incidence and Survival Rates of Malignant Central Nervous System Germ Cell Tumors in Korea, 2005-2012. Cancer Research and Treatment 49(2): 494-501, 2016

Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 98(8): E95-E97, 2014

Neuroendocrine tumors A population-based study of incidence and survival in Girona province, 1994–24. 2011

Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004. Cancer Epidemiology 35(6): E49-E54, 2012

Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. European Journal of Cancer 43(1): 144-148, 2006

Incidence and survival of Hodgkin lymphoma patients in Girona (Spain) over three decades: a population-based study. European Journal of Cancer Prevention 26 Joining Forces for Better Cancer Registration in Europe: S164-S169, 2017

Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993-2007. Leukemia Research 36(10): 1262-1266, 2012

Rapid increase in incidence of melanoma in situ in Girona (Spain), 1994-2005. Effectiveness of public education campaigns about early diagnosis. Actas Dermo-Sifiliograficas 101(6): 561-563, 2011

Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era. Cancer Epidemiology 38(3): 244-247, 2015